US2004161475A1PendingUtilityA1

Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds

51
Assignee: POLARX BIOPHARMACEUTICALS INCPriority: Oct 15, 1997Filed: Feb 12, 2004Published: Aug 19, 2004
Est. expiryOct 15, 2017(expired)· nominal 20-yr term from priority
Inventors:Ralph EllisonFred H. Marmelstein
A61P 35/04A61P 35/00A61P 35/02A61K 33/36A61P 17/00A61K 31/568A61K 45/06
51
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method of treating cancer in a human, which comprises administering to the human a combination of (i) a therapeutically effective amount of one or more arsenic compounds, and (ii) all-trans retinoic acid.  
     
     
         2 . The method of  claim 1 , wherein the arsenic compound is arsenic trioxide.  
     
     
         3 . The method of  claim 2 , wherein the arsenic trioxide is formulated as an ionic aqueous solution.  
     
     
         4 . The method of  claim 1 , wherein the total daily amount administered of the arsenic compound is from about 10 μg to about 200 mg.  
     
     
         5 . The method of  claim 1 , wherein the total daily amount administered of the arsenic compound is from about 0.5 mg to about 150 mg.  
     
     
         6 . The method of  claim 1 , wherein the total daily amount administered of the arsenic compound is from about 0.5 mg to about 70 mg.  
     
     
         7 . The method of  claim 1 , wherein the arsenic compound is administered parenterally.  
     
     
         8 . The method of  claim 1 , wherein the arsenic compound and the all-trans retinoic acid are administered intravenously.  
     
     
         9 . The method of  claim 1 , wherein the all-trans retinoic acid and the arsenic compound are administered in combination with an effective amount of at least one further therapeutic agent.  
     
     
         10 . The method of  claim 9 , wherein the further therapeutic agent is a chemotherapeutic or radiotherapeutic.  
     
     
         11 . The method of  claim 9 , wherein the further therapeutic agent is selected from the group consisting of etoposide, cisplatin, carboplatin, estramustine phosphate, vinblastine, methotrexate, hydroxyurea, cyclophosphamide, doxorubicin, 5-fluorouracil, taxol, diethylstilbestrol, VM-26(vumon), BCNU, all-trans retinoic acid, procarbazine, cytokines, therapeutic vaccines, and immunomodulators.  
     
     
         12 . The method of  claim 2 , wherein the dose is varied according to the body weight of the human.  
     
     
         13 . The method of  claim 2 , wherein the cancer is a hematopoietic cancer.  
     
     
         14 . The method of  claim 2 , wherein the cancer is a leukemia.  
     
     
         15 . The method of  claim 14 , wherein the leukemia is an acute myelogenous leukemia.  
     
     
         16 . The method of  claim 14 , wherein the leukemia is a chronic myelogenous leukemia.  
     
     
         17 . The method of  claim 2 , wherein the cancer is a lymphoma.  
     
     
         18 . The method of  claim 2 , wherein the cancer is a solid tumor.  
     
     
         19 . The method of  claim 2 , wherein the cancer has metastisized.  
     
     
         20 . The method of  claim 2 , wherein the all-trans retinoic acid is administered prior to the arsenic trioxide.  
     
     
         21 . The method of  claim 2 , wherein the all-trans retinoic acid is administered after the arsenic trioxide.  
     
     
         22 . The method of  claim 2 , wherein the all-trans retinoic acid and the arsenic trioxide are administered concurrently.  
     
     
         23 . The method of  claim 2 , wherein said cancer is a tumor of the central nervous system selected from the group consisting of neuroblastoma, retinoblastoma, glioblastoma or oligodendroglioma.  
     
     
         24 . The method of  claim 2 , wherein the cancer is refractory.

Join the waitlist — get patent alerts

Track US2004161475A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.